Orchestra BioMed Holdings (OBIO) Free Cash Flow (2021 - 2026)

Orchestra BioMed Holdings (OBIO) has 6 years of Free Cash Flow data on file, last reported at -$22.4 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 33.62% year-over-year to -$22.4 million in Q1 2026; TTM through Mar 2026 was -$54.8 million, a 0.56% decrease from a year earlier, with the FY2025 full-year figure at -$49.1 million, up 3.37% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$22.4 million, down from -$2.4 million in the prior quarter.
• Over the last five years, Free Cash Flow for OBIO reached as high as -$2.4 million in Q4 2025 and fell as low as -$22.4 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$11.7 million across 5 years, with a median of -$11.0 million in 2023.
• Across the five-year window, Free Cash Flow plunged 30411.53% in 2022 and surged 82.73% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$8.8 million in 2022, then dropped by 24.7% to -$11.0 million in 2023, then retreated by 24.36% to -$13.6 million in 2024, then jumped by 82.73% to -$2.4 million in 2025, then tumbled by 848.32% to -$22.4 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$22.4 million in Q1 2026, -$2.4 million in Q4 2025, and -$14.5 million in Q3 2025.